PtProtect® – Testing
Do you know all of the medications your patients take?
Our PtProtect® pain medication monitoring program can help protect your patient’s safety by minimizing the risks of unintended drug interactions. Our interpretive report clearly notes any discrepancies between pain medications prescribed and those detected.
Identify possible diversion
Patients who use illicit drugs are more likely to abuse and divert prescription medications either for financial gain or to fund an addiction to legal or illegal drugs. Family members may pilfer prescription drugs to self-treat or sell on the street.
The detailed PtProtect report, including interpretive comments, provides the documentation needed to address this issue with your patient in a follow-up conversation.
Responsibly monitoring patient medication adherence is a challenge. PeaceHealth Laboratories’ pain management panels are designed to monitor patient adherence with commonly used opiates, opioids and benzodiazepines, as well as to detect use of common illicit drugs.
PtProtect’s interpretive report provides a holistic view of the medications and substances the patient has taken and provides documentation needed to manage the controlled medication regimen for chronic pain patients.
Our test panels use the lowest available cut-off thresholds that reduce false negative results and confirms screened positives of commonly abused drugs.
(after last dose)
Opiates/Opioids by LC/MS/MS
|6-monoacetylmorphine||Heroin metabolite||<8 hours||5 ng/mL|
|Codeine*||Tylenol-3||1–3 days||5 ng/mL|
|Fentanyl||Duragesic, Actiq||1–2 days||2 ng/mL|
|Hydrocodone*||Vicodin and others||1–3 days||5 ng/mL|
|Hydromorphone*||Dilaudid||2–4 days||5 ng/mL|
|Meperidine||Demerol||1–2 days||5 ng/mL|
|Morphine*||MS Contin, Roxanol||1–3 days||5 ng/mL|
|Norfentanyl||Fentanyl metabolite||1–4 days||2 ng/mL|
|Oxycodone*||Oxycontin, Tylox, Percocet||1–3 days (SR 2–4 days)||5 ng/mL|
|Oxymorphone*||Numorphan, Opana||1–3 days (SR 1–4 days)||5 ng/mL|
Drug Screen by EIA and GC/MS
|Alcohol||Ethanol||2–14 hours||0.02/0.02 g/dL|
|Amphetamines/||Amphetamine||1–2 days||300/150 ng/mL|
|Barbiturates||Amobarbital||1–7 days||200/200 ng/mL|
|Benzodiazepines||Alprazolam metabolite||Therapeutic Dose:||200/50 ng/mL|
|Chlordiazepoxide metabolite||1–3 days|
|Diazepam metabolite||Extended Dosage:|
|Flunitrazepam metabolite||4–6 weeks|
|Cocaine||Cocaine metabolite||1–5 days||150/100 ng/mL|
|Marijuana||THC metabolite||Heavy User: 4–6 weeks||20/15 ng/mL|
|Moderate User: 2 weeks|
|Light User: 0–4 days|
|Methadone||Methadone metabolite||3–11 days||150/100 ng/mL|
|Phencyclidine||Phencyclidine||<8 days||25/25 ng/mL|
|Chronic Use: up to 30 days|
|Carisoprodol and metabolite||Soma||4 days||0.2 µg/mL|
|Buprenorphine and metabolite||Buprenex, Subutex, Suboxone||4 days||2 ng/mL|
|Ethanol metabolites (EtG, EtS)||Up to 80 hours after moderate-excessive ethanol use||500 ng/mL
|Tapentadol||Nucynta||1-2 days||25 ng/mL|
|Tramadol and metabolite||Ultram, Ultracet, Ryzolt||3 days||50 ng/mL|
* Denotes detection of free, non-conjugated drug.